The appeal of lung-on-a-chip systems is straightforward. Conventional two-dimensional cell cultures strip away the organised tissue interfaces, fluid dynamics and mechanical forces that define the respiratory microenvironment, while animal models suffer from interspecies differences that often fail to predict human responses. By combining microfabrication and microfluidic control with pulmonary cell culture, chip platforms can reproduce epithelial-endothelial interfaces, air-liquid interface culture, vascular perfusion and even breathing-related strain, features first brought together in the landmark 2010 human lung-on-a-chip by Huh and colleagues at Harvard. Since then, the design space has exploded, encompassing immune-competent models, patient-derived cells, high-containment infection systems and inhalation exposure devices.

Yet the review’s central message is provocative: more complexity does not automatically mean better science. Membrane thickness, pore size, porosity, stiffness and extracellular matrix functionalisation are not passive structural details; they actively shape transport, cell attachment, mechanical deformation and signalling between compartments. Small-pore polyester membranes, for example, favour a compartmentalised epithelial barrier, while larger pores are needed if researchers want immune cells to migrate across the interface. Barrier fidelity and leukocyte recruitment therefore demand different, sometimes conflicting, interface properties, and choosing between them depends entirely on the question being asked.

Fluidic strategy introduces a similar set of trade-offs. Perfusion delivers nutrients, removes waste, transports drug compounds and mechanically stimulates endothelial cells, but volumetric flow rate alone does not define the cellular environment, because wall shear stress also depends on channel geometry and fluid viscosity. Pump-driven systems offer precise control over flow profiles but increase dead volume, bubble risk and operational burden. Pump-free, gravity-driven rocking platforms simplify operation and reduce contamination risk in high-containment viral infection studies, at the cost of less precise control over instantaneous flow. The authors argue that studies should routinely report the flow-generation method, channel dimensions and calculated or measured shear stress so that perfusion-mediated transport can be distinguished from endothelial mechanostimulation.

Mechanical actuation, the defining capability of breathing chips, receives particularly careful treatment. The review emphasises that breathing motion is not a single condition but a family of variables spanning strain magnitude, frequency, waveform and actuation mechanism. Recent studies show these parameters matter enormously: cyclic stretch combined with airflow can accelerate mucociliary maturation of airway epithelium, and dynamic strain can modify how cells respond to inhaled toxicants. In one striking example, an orthotopic lung cancer chip demonstrated that breathing-related deformation altered tumour proliferation, invasion, dormancy and even responsiveness to tyrosine kinase inhibitors, implicating mechanical cues in epidermal growth factor receptor and MET signalling. Therapeutic response, in other words, cannot always be attributed to cellular genotype and drug exposure alone when the mechanical microenvironment itself modifies phenotype.

The same principle applies to exposure delivery and cellular composition. A next-generation breathing chip integrated with whole-cigarette-smoke exposure reported an approximately sixty percent reduction in barrier resistance and a 4.5-fold increase in interleukin-8 expression, with dynamic strain accelerating barrier disruption relative to static conditions, results that submerged chemical extracts could never reproduce. Cellular complexity, meanwhile, should be justified functionally rather than maximised blindly. An immune-competent lung-on-a-chip modelling severe influenza found that adding tissue-resident macrophages generated cytokine profiles more closely matching patient bronchoalveolar lavage data, but reproducing the broader inflammatory storm of severe infection required resident and circulating immune populations, perfusable microvasculature and a five-micrometre-pore interface that permitted immune migration. Complexity earned its place by enabling a predefined function.

Manufacturing and quality control emerge as underappreciated determinants of credibility. Small variations in channel dimensions, membrane position, bonding or actuator geometry can alter shear stress, strain transfer and barrier behaviour, and such technical variation can easily masquerade as biological variability. The review calls for predefined tolerances on critical device attributes, functional quality-control criteria including leak testing and sensor calibration, batch traceability, and documented fabrication parameters. It also cautions that switching fabrication methods, from soft lithography in polydimethylsiloxane to thermoplastic replication for scalable production, can change gas permeability, surface chemistry and compound adsorption, and should therefore trigger re-verification of critical engineering and biological endpoints rather than being treated as a neutral process change.

To organise the path from bench to regulatory relevance, the authors propose a five-stage framework anchored to a clearly defined context of use. The first stage, engineering verification, confirms that the device reproducibly generates its intended physical environment, from verified strain fields to delivered smoke exposure. The second, biological qualification, demonstrates that this environment supports the specific biological functions the application requires, such as barrier integrity, mucociliary activity or immune-cell migration. The third stage, disease or pharmacological validation, requires reproducible detection of the target response against appropriate comparators, as illustrated by a human alveolus chip that reproduced radiation-induced DNA damage, inflammation and barrier disruption and then evaluated prednisolone and lovastatin as candidate countermeasures.

The final two stages demand the most stringency. Human concordance requires direct comparison of chip outputs with patient-derived or clinical reference data, a standard met in part by the influenza chip’s cytokine benchmarking against patient samples, but the authors warn that such evidence should not be stretched into broader claims of clinical prediction. Predictive performance, needed when a context of use involves therapeutic or toxicological decision-making, requires predefined metrics such as sensitivity, specificity or response discrimination against characterised reference datasets. Deployment and regulatory readiness then asks whether qualified performance survives manufacturing scale-up, automation and transfer between independent laboratories. The framework deliberately distinguishes physiological resemblance from demonstrated concordance, and concordance from clinically anchored prediction, so that each claim carries only the weight its evidence supports.

The review’s conclusion is a call for discipline over dazzle. Prioritising validated, fit-for-purpose performance over maximal complexity, the authors contend, offers a more credible route toward reliable respiratory research tools, drug development platforms and eventual regulatory decision support. Standardisation, they argue, should target terminology, reporting of critical parameters, reference controls and inter-laboratory reproducibility rather than forcing identical device architectures, since legitimate applications genuinely require different designs. As regulators, including the United States Food and Drug Administration in recent draft guidance, increasingly frame new approach methodologies around context of use, the framework provides developers with a practical checklist: define the question and acceptance criteria before experimentation, report engineering parameters with tolerances, benchmark against prespecified comparators, incorporate human datasets when predictive claims are intended, and prove that performance holds across batches, operators and laboratories. If the field follows that path, the miniature lungs growing on chips today may earn the trust needed to influence tomorrow’s drug decisions.

Subject of Research: Engineering and translational validation of lung-on-a-chip microphysiological devices for respiratory disease modelling and drug testing

Article Title: Engineering Lung-on-a-chip microdevices for respiratory disease modelling and drug testing: A fit-for-purpose framework for design and translational validation

Article References: Cheong, S. Y., Liew, T. I. Z., Wong, C. K., Teng, X. X., Cha, X. Y., Ng, N. C.-S., Wong, R. S.-Y., & Goh, B. H. (2026). Engineering Lung-on-a-chip microdevices for respiratory disease modelling and drug testing: A fit-for-purpose framework for design and translational validation. Biomedical Microdevices, 28(3), Article 62. https://doi.org/10.1007/s10544-026-00849-3

Image Credits: AI Generated

DOI: 10.1007/s10544-026-00849-3

Keywords: lung-on-a-chip, microfluidics, organ-on-chip, respiratory disease modelling, drug testing, microphysiological systems, translational validation, mechanical strain, inhalation toxicology, quality control, regulatory science, context of use

The lung-on-a-chip technology employs microfluidic systems that replicate the physiological conditions of human lungs. This model not only supports human lung cells but also integrates immune cells to create a more holistic representation of lung functionality. The invention is particularly significant given the intricacies of the immune response to influenza, which can lead to severe respiratory complications. This model offers researchers the capacity to investigate these responses at both cellular and molecular levels, enabling a closer examination of the pathogen-host interaction.

In their recent study, the researchers, including Ringquist, Bhatia, and Chatterjee, have meticulously detailed the fabrication and operational parameters of their lung-on-a-chip device. The chip is designed to facilitate the flow of air and immune cells, akin to the natural flow within human lungs. Such a set-up allows for real-time monitoring of cellular responses to viral infections, potentially leading to insights into how the immune system reacts under severe influenza conditions. This capability is crucial for dissecting the immunopathology associated with various influenza strains, which often vary in virulence and transmissibility.

A particular highlight of this research is the multifunctionality of the lung-on-a-chip. By enabling the simulation of both viral infection and immune response, researchers can observe the impacts of various therapeutic interventions in a controlled environment. For instance, the model can be used to test antiviral drugs or vaccine candidates, providing invaluable preclinical data that could streamline the transition to human trials. This approach has the potential to significantly shorten the drug development timeline, offering new hope for timely interventions against influenza outbreaks.

The incorporation of immune cells into the lung-on-a-chip model further amplifies its relevance in modern biomedical research. Traditional models often overlook the contributions of immune responses in disease progression, leading to a lack of understanding of their roles. By embedding these immune cells within the chip, researchers can monitor cytokine release, cell signaling pathways, and other immune interactions as they occur in real-time, generating a wealth of data that can inform both basic science and clinical applications.

Additionally, the team demonstrates the ability to model different respiratory conditions, adjusting parameters such as airflow and pressure to mimic disease states more accurately. This versatility opens avenues for not only researching influenza but also other respiratory pathogens, including coronaviruses and bacteria, enabling the creation of comprehensive studies on respiratory infections as a whole. The implications for public health are profound, as this technology can inform vaccine development and epidemic preparedness strategies.

Moreover, the lung-on-a-chip technology is poised to reduce the reliance on animal models, addressing significant ethical concerns in biomedical research. By providing a reliable alternative that mirrors human physiology more closely than traditional animal models, researchers can conduct studies with a more humane approach, all while gathering data that is more applicable to human health. This shift in paradigm aligns with the move toward human-centered research methodologies in biomedical fields.

The initial experiments conducted using this novel lung-on-a-chip have already yielded promising results, elucidating the cellular dynamics in response to influenza infection. Early data indicate that the model successfully mimics the inflammatory responses observed in infected human lungs, characterizing the release of specific immune mediators that contribute to disease pathology. These findings not only reinforce the accuracy of the lung-on-a-chip model but also validate its potential for uncovering insights into viral pathogenesis.

Further investigations using the device will be oriented towards understanding the differential responses of various influenza strains. Given the ongoing evolution of influenza viruses and their capacity to mutate rapidly, a model that can simulate these variations may be crucial in anticipating how new strains could affect public health. The ability to swiftly adapt the chip apparatus for different viral strains could lead to significant advancements in vaccine formulation and antiviral treatments.

The integration of cutting-edge imaging technologies with the lung-on-a-chip offers an additional dimension to the research capabilities. Techniques such as live-cell imaging can be employed to visualize interactions at the cellular level, providing an unprecedented view of the cellular mechanisms in play during an influenza infection. This level of detail could illuminate previously hidden aspects of viral pathology and will likely lead to groundbreaking discoveries in the field of immunology.

As the research community begins to explore the full potential of the lung-on-a-chip technology, collaborative efforts among scientists, clinicians, and policymakers will be essential. Sharing data across institutions will accelerate knowledge transfer and inspire innovative approaches to tackling viral infections. Ultimately, by uniting multiple disciplines around this platform, the scientific community can deepen its understanding of respiratory diseases and foster the development of more effective interventions.

In conclusion, the development of an immune-competent lung-on-a-chip currently signifies a significant leap forward in modeling human respiratory responses to influenza. By providing a realistic, controlled environment for studying viral infections and immune reactions, this groundbreaking research lays the groundwork for future explorations into respiratory diseases. The implications of this technology extend far beyond influenza, presenting an opportunity to fundamentally change how researchers approach studies of viral infections and their corresponding immune responses. The potential to expedite drug development and enhance our understanding of respiratory health and disease make the lung-on-a-chip a prominent topic in the realm of medical research.

Subject of Research: Immune-competent lung-on-a-chip for modeling severe influenza infection response.

Article Title: An immune-competent lung-on-a-chip for modelling the human severe influenza infection response.

Article References:

Ringquist, R., Bhatia, E., Chatterjee, P. et al. An immune-competent lung-on-a-chip for modelling the human severe influenza infection response.
Nat. Biomed. Eng (2025). https://doi.org/10.1038/s41551-025-01491-9

Image Credits: AI Generated

DOI: 10.1038/s41551-025-01491-9

Keywords: lung-on-a-chip, influenza, immune response, viral infection, biomedical engineering.